## Chelerythrine

®

MedChemExpress

| Cat. No.:          | HY-N2359  |                |  |
|--------------------|---|----------------|--|
| CAS No.:           | 34316-15-9  |                |  |
| Molecular Formula: | C <sub>21</sub> H <sub>18</sub> NO <sub>4</sub>   | 0              |  |
| Molecular Weight:  | 348.37  | N <sup>+</sup> |  |
| Target:            | PKC; Bcl-2 Family; Apoptosis; Autophagy; Beta-lactamase                                   |                |  |
| Pathway:           | Epigenetics; TGF-beta/Smad; Apoptosis; Autophagy; Anti-infection                          |                |  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |                |  |

| gy; Beta-lactamase<br>s; Autophagy; Anti-infection<br>ommended conditions in the Certificate of |  |
|---|--|
|   |  |

Product Data Sheet

| BIOLOGICAL ACTIV          | ТҮ ————  |  |  |
|---------------------------|--|--|--|
| Description               | Chelerythrine is a natural alkaloid, acts as a potent and selective Ca <sup>2+</sup> /phospholopid-dependent PKC antagonist, with an IC <sub>50</sub> of 0.7 μM <sup>[1]</sup> . Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity <sup>[2]</sup> . Chelerythrine inhibits the BclXL-<br>Bak BH3 peptide binding with IC <sub>50</sub> of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy <sup>[3][4]</sup> .   |  |  |
| IC <sub>50</sub> & Target | ΡΚC<br>0.7 μΜ (IC <sub>50</sub> )  |  |  |
| In Vitro                  | <ul> <li>Chelerythrine (48 h) inhibits the growth of L-1210 cells (IC<sub>50</sub>: 0.53 uM)<sup>[1]</sup>.</li> <li>Chelerythrine (0-20 μM, 24 h) inhibits cell viability, induces apoptosis and autophagy in A549 and NCI-H1299 cells<sup>[4]</sup>.</li> <li>Chelerythrine (0-5 μM, 24 or 48 h) induces apoptosis in BclXL-overexpressing SH-SY5Y cells<sup>[3]</sup>.</li> <li>Chelerythrine (2.5-10 μM, 16 h) induces mitochondrial depolarization (decrease in mitochondrial potential) in SH-SY5Y cells, and stimulates release of CytC from isolated mitochondria<sup>[4]</sup>.</li> <li>Chelerythrine (0-100 ng/mL, 24 h) reduces the LPS induced production of NO and TNF-α in primary macrophages<sup>[5]</sup>.</li> <li>Chelerythrine (MIC: 0.156 mg/mL) shows antibacterial activities against Gram-positive bacteria, Staphylococcus aureus (SA), MRSA, and extended spectrum β-lactamase S. aureus (ESBLs-SA)<sup>[6]</sup>.</li> <li>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</li> <li>Western Blot Analysis<sup>[4]</sup></li> </ul> |  |  |
|                           | Cell Line:   | A549 and NCI-H1299 cells   |  |
|                           | Concentration:   | 10, 15, 20 μM  |  |
|                           | Incubation Time:   | 24 h   |  |
|                           | Result:  | Induced expression of LC3-II in a beclin 1-dependent way.  |  |
| In Vivo                   | Chelerythrine (5 mg/kg, i.p.,<br>restores renal function in new<br>Chelerythrine (1-10 mg/kg, i.<br>survival rate, decreased seru<br>MCE has not independently o   | daily) attenuates partial unilateral ureteral obstruction (UUO) induced kidney injury, and<br>onatal rats <sup>[2]</sup> .<br>p., at 24 and 1 h before injection of 100 μg/kg LPS) shows anti-inflammatory effects (increased<br>Im nitrite and TNF-α level) in LPS induced mice endotoxic shock model <sup>[5]</sup> .<br>confirmed the accuracy of these methods. They are for reference only. |  |

| Animal Model:   | Unilateral ureteral obstruction (UUO) induced neonatal rats <sup>[2]</sup>  |
|-----------------|---|
| Dosage:         | 5 mg/kg   |
| Administration: | i.p., daily   |
| Result:         | Attenuated kidney injury (Increased kidney weight and restored renal function).<br>Inhibited UUO-induced upregulated kidney injury molecule-1 expression, apoptosis, and<br>renal fibrosis. |

## **CUSTOMER VALIDATION**

- Cell Commun Signal. 2021 Oct 11;19(1):103.
- J Headache Pain. 2022 Mar 8;23(1):35.
- Phytother Res. 2023 Jul 4.
- Cancer Cell Int. 2023 Jun 17;23(1):117.
- Front Pharmacol. 13 May 2021.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Li W, et al. Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway. Inflammation. 2012 Dec;35(6):1814-24.

[2]. He N, et al. Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam. BMC Complement Altern Med. 2018 Sep 26;18(1):261.

[3]. Herbert JM, et al. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990 Nov 15;172(3):993-9.

[4]. Shi B, et al. Protein kinase C inhibitor chelerythrine attenuates partial unilateral ureteral obstruction induced kidney injury in neonatal rats. Life Sci. 2019 Jan 1;216:85-91.

[5]. Chan SL, et al.Identification of chelerythrine as an inhibitor of BclXL function.J Biol Chem. 2003 Jun 6;278(23):20453-6.

[6]. Tang ZH, et al.Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells.Redox Biol. 2017 Aug;12:367-376.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Des: Park Dr. Switz O. Magnetick hungting NL 00052 USA

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA